Table legend: #, number of (injections); A.C., all-cause mortality; Aflib., aflibercept; AMD, age related macular degeneration; Bev., bevacizumab; CRVO, central retinal vein obstruction; CVA, cerebrovascular accident; dec., decreased; DME, diabetic macular edema; eGFR, estimated glomerular filtration rate; HTN, hypertension; MI, myocardial Infarction; n, number of study subjects; Ran, ranibizumab; RT, randomized trial; Ran/Bev Trial N, Ranibizumab Bevacizumab Trial Network; SAE, serious adverse event; VEGF, vascular endothelial growth factor; VEGFi, vascular endothelial growth factor inhibitors. Adapted from Phadke, CKJ 2021 open access [13].